Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

BIM BH3 apoptosis-inducing peptide for cancer research

BIM BH3 - apoptosis-inducing peptide US$392.60 Excluding tax and shipping fees In stock Description About BIM BH3 - apoptosis-inducing peptide BIM BH3 is an apoptosis-inducing peptide for cancer research. The BIM BH3 peptide, H-MRPEIWIAQELRRIGDEFNA-OH from JPT

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

BIM BH3 - apoptosis-inducing peptide

US$392.60

Excluding tax and shipping fees

In stock

Description

About BIM BH3 - apoptosis-inducing peptide

BIM BH3 is an apoptosis-inducing peptide for cancer research. The BIM BH3 peptide, H-MRPEIWIAQELRRIGDEFNA-OH from JPT is produced under strict quality control and quality management.

BIM BH3 apoptosis-inducing peptide - Specifications

Peptide sequence: H-MRPEIWIAQELRRIGDEFNA-OH2

Amount: 5 mg

Purity: > 95% (HPLC/MS)

Counterion: TFA

Delivery Format: Freeze-dried in plastic vial

Application(s): Cancer research

Condition(s)/Topic(s): Cancer

Standard Delivery Time: approx. 3 weeks

Non-RGD Cancer Peptides from JPT

Cancer peptides are widely used to develop targeted diagnostic and therapeutic approaches. They offer different functionalities such as binding tumor-associated receptors, interacting with cellular membranes, or interfering with tumor microenvironment. Depending on the application, these mechanisms enable specific delivery, tumor imaging, and tumor cell killing with low side effects.JPT offers a wide portfolio of high-quality cancer peptides engineered for robust and reproducible research in oncology including RGD and non-RGD cancer peptides.

Benefits of JPT’s Non-RGD Cancer Peptides

Each peptide quality controlled and guaranteed for identity and purity

CoA and HPLC-MS data available

High batch-to-batch consistency

Synthesis protocols designed to avoid toxic contaminants and side products

Provision of freeze dried aliquots for enhanced stability

Proven track record for applications in clinical studies

References

References for BIM BH3 - apoptosis-inducing peptide

ReferencesRead References with Peptides made by JPT

Documentation

Documentation for BIM BH3 - apoptosis-inducing peptide

BIM-BH3-apoptosis-inducing-peptide.pdf

Properties

Properties of BIM BH3 - apoptosis-inducing peptide

5 mg

T-cell immunity

Cancer peptides, Cancer peptides Non-RGD

Cancer

Freeze-dried in plastic vial

Human

Bcl-2-related protein

>95% (HPLC-MS)

No

Further Information to BIM BH3 - apoptosis-inducing peptide

Values

H-MRPEIWIAQELRRIGDEFNA-OH

Related Products

Related Products

Bak BH3

US$220.05

iRGD Peptide (cyclo-CRGDKGPDC), CAS 1392278-76-0

US$177.67

Proapoptotic Peptide KLA

US$326.22

RGD-4C, CAS 332179-76-7

US$282.50

PAR-4 agonist peptide, CAS 352017-71-1

US$514.80

GRGD-acid, CAS 97461-81-9

Cecropin A Peptide

US$381.12

T3 Peptide,Tumstatin (69-88), human

US$853.11

Azurin p28 peptide, CAS 897026-25-4

US$334.90

P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →